Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-02
2011-08-02
Schwadron, Ronald (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S142100, C424S159100, C435S339000, C435S975000, C530S388150, C530S388300
Reexamination Certificate
active
07988972
ABSTRACT:
The Epstein-Barr virus (EBV) specific polypeptides ETFTETWNRFITHTE (SEQ. ID NO: 1), GMLEASEGLDGWIHQ (SEQ. ID NO:2), HQQGGWSTLIEDNIP (SEQ. ID NO:3), and KQKHPKKVKQAFNPL (SEQ. ID NO:4) are among those disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.
REFERENCES:
patent: 3654090 (1972-04-01), Schuurs et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 4016043 (1977-04-01), Schuurs et al.
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4281061 (1981-07-01), Zuk et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4879213 (1989-11-01), Fox et al.
patent: 5126259 (1992-06-01), Tada et al.
patent: 0 173 254 (1986-03-01), None
patent: 0 280 813 (1988-09-01), None
patent: WO 91/08224 (1991-06-01), None
patent: WO 94/06470 (1994-03-01), None
patent: WO 94/08597 (1994-04-01), None
Foong, Y.T. et al., “Serum and Salivary IgA Antibodies Against a Defined Epitope”,Int. J. Cancer, 1990, 45, 1061-1064.
Linde, A. et al., “Evaluation of Enzyme-Linked Immunosorbent Assays”,Journal of Infectious Diseases, 1990, 903-909.
Rhodes, G. et al., “Human Immune Responses to Synthetic Peptides”,J. of Immunol., Jan. 1985, 134(1), 211-216.
Smith, R.S. et al., “A Synthetic Peptide for Detecting Antibodies”,Journal of Infectious Diseases, Nov. 1986, 154(5), 885-889.
Baer, R., DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome,Nature, Jul. 1984, 310, 207-211.
Okano, M. et al., “Epstein-Barr Virus and Human Diseases”,Clinical Microbiology Reviews, Jul. 1988, 300-312.
Luka, J. et al., “A Sensitive Enzyme-Linked Immunosorbent Assay”,Journal of Immunol. Methods, 1984, 67, 145-156.
Halprin, J. et al., “Enzyme-Linked Immunosorbent Assay of Antibodies”,Annals of Internal Medicine, 1986, 104, 331-337.
Pearson, G., “Identification of Polypeptide Components of the Epstein-Barr . . . ”,Journal of Virology, Jul. 1983, 193-201.
Pearson, G.et al., “Identification of an Epstein-Barr Virus Early Gene Encoding a Second Component of the Restricted Early Antigen Complex”,Virology, 1987, 160,151-161.
Motz, M. et al., “Expression of the Epstein-Barr Virus 138 kDa Early Protein”,Gene, 1986, 42, 303-312.
Baer et al., DNA Sequence and Expression of the B95-8 Epstein Barr Virus Genome, Nature 310: 207-211 (Jul. 1984).
Burton et al., “A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals” Proc. Natl. Acad. Sci. USA vol. 88: 10134-10137 (Nov. 1991).
Curtiss, L.K. et al., “Localization of Two Epitopes of Apolipoprotein A-I That are Exposed on Human High Density Lipoproteins Using Monoclonal Antibodies and Synthetic Peptides”, J. Biol. Chem., vol. 263, No. 27: 13779-13785 (Sep. 1988).
Diener et al., “Specific Immunosuppression by Immunotoxins Containing Daunomycin” Science vol. 231: 148-150 ( Jan. 1986).
Dillner et al., “Antibodies Against a Synthetic Peptide Identify the Epstein-Barr Virus-Determined Nuclear Antigen” Proc. Natl. Acad. Sci USA 81: 4652-4656 (Aug. 1984).
Douillard, J.Y. and Hoffman, “Monoclonal Antibodies Specific Immunotherapy of Gastrointestinal Tumors” T., Hyrbidoma 5 Supp 1: S139-S149 (Jul. 1986).
Eisenlohr et al., “Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes” J. Exp Med. vol. 175: 481-487 (Feb. 1992).
Fox et al., “Synthetic Peptide Derived From the Epstein-Barr Virus Encoded Early Diffuse Antigen (EA-D)-Reactive with Human Antibodies” J. Clin. Lab. Anal. 1:140-145 (1987).
Greiner et al., “Recombinant Interferon Enhances Monoclonal Antibody-Targeting of Carcinoma Lesions in Vivo” Science vol. 235, No. 4791: 895-898 ( Feb. 1987).
Henle et al, “Epstein-Barr Virus Specific Diagnostic Tests in Infectious Mononucleosis” Human Pathology vol. 5, No. 5: 551-565 (Sep. 1974).
Henle et al., “Demonstration of Two Distinct Components in the Early Antigen Complex of Epstein-Barr Virus-Infected Cells” Int. J. Cancer vol. 8, No. 3: 272-282 (Nov. 1971).
Herlyn et al., “Anti-Idiotypic Antibodies Bear the Internal Image of a Human Tumor Antigen” Science vol. 232, No. 4746: 100-102 (Apr. 1986).
Hinuma, Y. et al., “Immunofluorescence and Herpes-Type Virus Particles in the P3HR-1 Burkitt Lymphoma Cell Line” J. Virol. vol. 1, No. 5: 1045-1051 (Oct. 1967).
Jackman et al., “Expression of Epstein-Barr Virus gp350 as a Single Chain Glycoprotein for an EBV Subunit Vaccine” Vaccine 17: 660-668 (1999).
Jemmerson, “Effects of Conformation, Amino Acid Sequence, and Carrier Coupling on the Immunological Recognition of Peptide and Protein Antigens” Effects on Immunological Recognition of Peptides in Medicine And Biology, Edited by Zegers, Boersma, Classen, CRC Press Inc., New York Chapter 16, 213-225 (1995).
Köhler and Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity” Nature: vol. 256, No. 5517 495-497 (Aug. 1975).
Lenard, J. et al., “Use of Hydrogen Fluoride in Merrifield Solid-Phase Peptide Synthesis” J. Am. Chem. Soc. vol. 89, No. 1: 181-182 (Jan. 1967).
Lerner, “Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity” Nature 299: 592-596 (Oct. 1982).
Luka et al., “A Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) Against the Major EBV-Associated Antigens. I. Correlation between ELISA and Immunofluorescence Titers Using Purified Antigens” J. Immunol. Methods 67: 145-156 (1984).
Merrifield, “Solid Peptide Synthesis. I. The Synthesis of a Tetrapeptide”, J. Am. Chem. Soc. 85: 2149-2154 (Jul. 1963).
Oi et al., “Chimeric Antibodies”, Bio Techniques vol. 4, No. 3: 214-221 (May/Jun. 1986).
Ortho Diagnostic Systems, Inc. ORTHO *Eptstein-Barr Virus EA(D+R)-IgG Antibody ELISA Test for Detection of IgG Antibodies to the Early Antigen (EA) Diffuse and Restricted (D&R) Components of the Epstein-Barr Virus (EBV), Product Code 520025, 1-38 (Draft revised Aug. 20, 1993).
Pearson et al., “Application of Epstein-Barr Virus (EBV) Serology to the Diagnosis of North American Nasopharyngeal Carcinoma” Cancer 51: 260-268 (Jan. 1983).
Pearson et al. “Identification of an Epstein-Barr Virus Early Gene Encoding a Second Component of the Restricted Early Antigen Complex” Virology 160: 151-161 (1987).
Pothen et al., “Identification of T- and B-Cell Epitopes Associated with a Restricted Component of the Epstein-Barr Virus-Induced Early Antigen Complex” Int. J. Cancer 53: 199-204 (1993).
Pothen et al., “Human T-Cell Recognition of Epstein Barr Virus-Induced Replication Antigen Complexes” Int. J. Cancer 49: 656-660 (1991).
Rhodes et al., “Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen” J. Immunol vol. 134, No. 1: 211-216 (Jan. 1985).
Smith et al. , “Antibodies to an Epstein-Barr Virus Nuclear Antigen Synthetic Peptide in Infectious Mononucleosis” Am. J. Clin. Pathology vol. 92 No. 4: 447-451 (Oct. 1989).
Spira et al., “The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay” J. Immunol. Methods 74: 307-315 (1984).
Steplewski et al., “Isolation and Characterization of Anti-Monosialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants” Proc. Natl. Acad. Sci., USA, vol. 82: 8653-8657 (Dec. 1985).
Stewart and Young, “Laboratory Techniques in Solid Phase Peptide Synthesis” Solid Phase Peptides Synthesis (W. H. Freeman & Company, San Francisco, Chapter 2 pp. 27-64 (1969).
Sun et al., “Chimeric Antibodies with 17-1A-
Parks D. Elliot
Pearson Gary R.
Smith Richard S.
Varghese Susan Pothen
Ortho-Clinical Diagnostics, Inc.
Schwadron Ronald
Woodcock & Washburn LLP
LandOfFree
Immunoreactive peptides from Epstein-Barr virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoreactive peptides from Epstein-Barr virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoreactive peptides from Epstein-Barr virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2760639